We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Obalon Therapeutics Inc | NASDAQ:OBLN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | 2.81 | 2.87 | 0 | 01:00:00 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * ARMISTICE CAPITAL, LLC |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol ReShape Lifesciences Inc. [RSLS] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below) | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock, $.001 par value per share | 2409342 | D (1) | |
Common Stock, $.001 par value per share | 2409342 | I | See Footnote 1 |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Series A Warrants | (2) | (2) | Common Stock | 1479713 | (2) | D (1) | |
Series A Warrants | (2) | (2) | Common Stock | 1479713 | (2) | I | See Footnote 1 |
Series E Warrants | (3) | (3) | Common Stock | 1479713 | (3) | D (1) | |
Series E Warrants | (3) | (3) | Common Stock | 1479713 | (3) | I | See Footnote 1 |
Series G Warrants | (4) | (4) | Common Stock | 676440 | (4) | D (1) | |
Series G Warrants | (4) | (4) | Common Stock | 676440 | (4) | I | See Footnote 1 |
Series G Warrants | (5) | (5) | Common Stock | 676440 | (5) | D (1) | |
Series G Warrants | (5) | (5) | Common Stock | 676440 | (5) | I | See Footnote 1 |
Warrant | (6) | (6) | Common Stock | 2254800 | (6) | D (1) | |
Warrant | (6) | (6) | Common Stock | 2254800 | (6) | I | See Footnote 1 |
Warrant | (7) | (7) | Common Stock | 563700 | (7) | D (1) | |
Warrant | (7) | (7) | Common Stock | 563700 | (7) | I | See Footnote 1 |
Total Return Swap | (8) | (8) | Common Stock | 283000 | (8) | D (1) | |
Total Return Swap | (8) | (8) | Common Stock | 283000 | (8) | I | See Footnote 1 |
Total Return Swap | (9) | (9) | Common Stock | 108333 | (9) | D (1) | |
Total Return Swap | (9) | (9) | Common Stock | 108333 | (9) | I | See Footnote 1 |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10022 | X | ||||
Boyd Steven C/O ARMISTICE CAPITAL, LLC 510 MADISON AVENUE, 7TH FLOOR NEW YORK, NY 10022 | X |
Signatures | ||
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member | 6/22/2021 | |
**Signature of Reporting Person | Date | |
/s/ Steven Boyd | 6/22/2021 | |
**Signature of Reporting Person | Date |
1 Year Obalon Therapeutics Chart |
1 Month Obalon Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions